Drug Trial Radar · NCT05882695
Study of SPG302 in Healthy Volunteers and ALS Participants
Last checked: Nov 19, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Jul 3, 2023
Primary completion
Jun 27, 2025
Study completion Jun 27, 2025
Sponsor
- Lead sponsor
- SpinogenixIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
SPG302Drug
synthetic small molecule
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability in healthy volunteers (SAD cohort)Time frame: 7 days
- Safety and tolerability in healthy volunteers (SAD food effect cohort)Time frame: 15 days
- Safety and tolerability in healthy volunteers (MAD cohort)Time frame: 12 days
- Safety and tolerability in participants with ALSTime frame: 60 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Macquarie University
North Ryde, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Flinders Medical center
Adelaide, South Australia, Australia
Nucleus Melbourne (healthy volunteers)
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.